Sarepta Therapeutics Q1 revenue falls on lower ELEVIDYS sales

Sarepta Therapeutics

06/05/2026 21:28

Overview

U.S. rare disease drugmaker's Q1 revenue fell 2% yr/yr

Company achieved positive net income for Q1 2026

Lower ELEVIDYS sales offset by collaboration and contract manufacturing revenue growth

Outlook

Sarepta reiterates FY 2026 net product revenue guidance of $1.2-$1.4 bln

Company expects FY 2026 non-GAAP R&D and SG&A expenses of $800 mln-$900 mln

Company says commercial portfolio has begun to stabilize, with ELEVIDYS positioned to return to growth

Result Drivers

ELEVIDYS SALES DECLINE - Lower volume of ELEVIDYS sales due to updated label restricting use to ambulatory patients

COLLABORATION REVENUE - Increase in collaboration revenue from Roche milestone and declined option on program rights

LOWER OPERATING EXPENSES - Decrease in R&D and SG&A expenses due to absence of prior year licensing fees and restructuring

Company press release: ID:nBw7r84gLa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$730.8 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy", 14 "hold" and 5 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Sarepta Therapeutics Inc is $20.00, about 8.2% below its May 5 closing price of $21.79

The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)